AERIUS (Ebastine) is an antihistamine that is applied across therapeutic domains where symptomatic support is needed. The use of this medication is aligned with its indications for easing symptoms in situations where patients experience physical discomfort, such as sneezing, runny nose, and itchy eyes.

It is relevant for easing symptoms in conditions involving episodic or fluctuating manifestations, including seasonal allergic rhinitis, perennial allergic rhinitis (hay fever), and chronic idiopathic urticaria (hives). This medication is applied in scenarios where additional symptomatic support is required, particularly in clinical settings involving acute or disruptive symptom patterns. It assists with maintaining functional stability during periods of heightened discomfort, offering supportive relief when symptoms interfere with routine activities.

“This approach contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Support for Allergic Conjunctivitis (symptoms related to inflammatory or irritative states of the eye).

Regulatory References

1. Irish Health Products Regulatory Authority (HPRA) Summary

AERIUS, which contains the active ingredient Ebastine, is generally prescribed for adults and adolescents from 12 years of age to treat symptoms of allergic rhinitis (seasonal and perennial) and chronic idiopathic urticaria (hives).

Contraindications and Precautions

Like many medications, Ebastine is not suitable for everyone. It is generally contraindicated (should not be used) in individuals who have a known hypersensitivity or allergy to ebastine or any other ingredient in the formulation.

Special caution is advised for patients with certain pre-existing conditions. Use should be avoided or closely monitored by a healthcare professional in cases of:

Patients should always consult a physician to ensure Ebastine is appropriate for their specific health profile.

Interactions with other medicines and products

The official regulatory documentation for Ebastine defines interactions based on two primary mechanisms: metabolic alteration and pharmacodynamic risk.

Documented Pharmacokinetic Interactions

Ebastine is primarily metabolized by the cytochrome P450 enzyme system, predominantly CYP3A4. Co-administration with certain medicinal products alters the plasma concentration of Ebastine and its active metabolite, carebastine, which requires caution as stated in regulatory labels.

• Increased Exposure: Potent enzyme inhibitors like Ketoconazole, Erythromycin, and Itraconazole can lead to increased plasma concentrations of Ebastine and carebastine due to reduced metabolism.
• Decreased Exposure: Potent enzyme inducers, such as Rifampicin, can lead to decreased plasma concentrations of carebastine, potentially reducing the overall anti-allergic effect.

Pharmacodynamic and Other Interactions

Co-administration with other medicinal products known to prolong the QTc interval carries an increased risk of QTc prolongation due to an additive effect on cardiac repolarization. This includes combinations with the enzyme inhibitors listed above.

• Food Interaction: Administration with food is documented to increase the exposure (AUC) of carebastine by 1.5- to 2.0-fold, though this alteration is not officially associated with a modification of the clinical effect.
• Alcohol: No specific interaction has been reported or documented with the consumption of alcohol.

Population-Specific Notes

The half-life of carebastine is prolonged in patients with severe hepatic impairment. Due to this altered clearance, the regulatory labeling stipulates a maximum daily dose constraint for this specific patient population.

Ebastine, an inactive pro-drug, is metabolically converted by hepatic cytochrome P450 3A4 to its primary active metabolite, carebastine. Carebastine functions as a selective inverse agonist at the peripheral histamine H1 receptor, a G-protein coupled receptor. The active metabolite exhibits high affinity for these H1 receptors located on target cells in peripheral tissues, including the respiratory tract and vasculature, while demonstrating negligible penetration of the blood-brain barrier. By stabilizing the H1 receptor in its inactive conformation, carebastine competitively prevents the binding and functional activation of endogenous histamine. This inverse agonism results in the reduction of intracellular signaling cascades typically mediated by the H1 receptor, such as the downstream activation of transcription factors like NF- κB and AP-1. The system-level physiological consequence is the modulation of histamine-induced actions on capillary permeability and smooth muscle contraction in H1-expressing tissues.

Official Administration Guidelines for AERIUS (Ebastine)

Ebastine is an antihistamine intended for oral administration and is typically taken once daily. Standard administration rules are defined to ensure correct use.

Dosage and Administration Schedule

Note on Frequency: Ebastine is to be taken once daily (q.d.), which provides a sustained effect over 24 hours.

Administration Specifics

Ebastine can be taken with or without food, meaning the timing relative to meals is not restrictive for administration. The method of intake depends on the dosage form:

• Film-coated tablets must be swallowed unchewed with liquid.
• Orodispersible tablets (ODT) are placed on the tongue where they dissolve rapidly; no water or other fluid is required for swallowing. These tablets should be handled with dry hands and taken immediately upon removal from the blister.

Duration of Use: Treatment may be prolonged until symptoms resolve, with clinical observations noting experience for continuous use up to one year for allergic rhinitis.

Ebastine: Recent Clinical Evidence

Ebastine is classified as a long-acting, second-generation H1-receptor antagonist with its primary therapeutic effect attributed to its active metabolite, carebastine. This class of antihistamines is preferred due to its selective binding to peripheral H1-receptors and minimal penetration of the blood-brain barrier, which typically results in a low risk of sedation at standard doses.

Chronic Spontaneous Urticaria (CSU)

Controlled clinical trials have examined ebastine's role in managing Chronic Spontaneous Urticaria (CSU), characterized by hives and itching lasting six weeks or more. Studies involving patients with CSU suggest that ebastine 10 mg once daily may improve symptoms, including the severity of itching and the number of wheals, when compared to placebo. In some instances of insufficient symptom control, guidelines suggest the potential for dose escalation of second-generation H1-antihistamines, including ebastine, up to four times the standard dose. Research on higher doses of ebastine (up to 40 mg) in patients with refractory CSU indicates that this approach may be well tolerated and associated with further reductions in urticaria activity scores.

Allergic Rhinitis (AR)

In studies addressing Seasonal and Perennial Allergic Rhinitis (AR), ebastine 10 mg once daily has been shown to reduce overall symptom scores compared to placebo. Comparative trials suggest that ebastine 10 mg generally exhibits similar efficacy to other standard second-generation antihistamines, such as cetirizine and loratadine, in relieving AR symptoms. Some analyses of clinical trial data suggest a trend toward greater efficacy in reducing symptoms, including nasal congestion, with an increased dose of ebastine (20 mg) over the standard 10 mg dose in certain patient populations.

Common questions about AERIUS (Ebastine) (FAQ)

Q: How quickly should I expect to feel the initial effects of Ebastine after taking a dose?

Studies and official information indicate that the active substance, carebastine, reaches its peak concentration in the bloodstream roughly between 2.5 and 5.7 hours after you take the medicine. This time frame represents when the highest concentration of the drug's active substance is generally measured in the blood.

Q: Does the relief from a single dose of Ebastine last for a full 24 hours?

Regulatory documents indicate that Ebastine is designed to provide a sustained antihistamine effect. It is intended for once-daily dosing, which is documented to provide relief from symptoms over a 24-hour period.

Q: What are the general guidelines about taking Ebastine during pregnancy?

Official documentation advises against taking this medicine during pregnancy, or if you are planning to become pregnant, unless a doctor specifically determines that its use is essential for you. A healthcare professional should be consulted for guidance regarding any medication use during this period.

Q: Is Ebastine excreted in breast milk according to regulatory documents?

It is not known whether the active substance is excreted in human milk. Official sources generally include a recommendation to avoid the use of Ebastine while breastfeeding as a precautionary measure.

Q: What is the lowest age at which a child can be given Ebastine?

Standard regulatory labeling for Ebastine states that it is recommended for use in adults and adolescents aged 12 years and older for its main therapeutic indications, such as allergic rhinitis and urticaria.

Q: Can taking specific antibiotics along with Ebastine cause issues?

Caution is advised when using Ebastine alongside certain macrolide antibiotics, such as Erythromycin or Clarithromycin. This is because these combinations may lead to increased plasma concentrations of Ebastine and its active metabolite, which is why caution is advised.

Q: Why is caution advised in patients with severe hepatic impairment (severe liver problems)?

Official documentation states that a dose adjustment is generally not necessary for patients with renal impairment (kidney problems). Caution regarding dose constraints is specifically advised for patients with severe hepatic impairment (severe liver problems) due to altered clearance of the drug.

Q: Is Ebastine the same type of medication as an antibiotic?

No. Ebastine is classified as a selective H₁-receptor antagonist, which is a type of antihistamine. Its function is to block the effects of histamine in the body, not to fight bacterial infections like an antibiotic.

Q: What is the difference between the drug name AERIUS and the active substance Ebastine?

Ebastine is the international non-proprietary name (INN) for the active chemical ingredient in the medicine. AERIUS is one of the common brand or trade names used by a pharmaceutical company to market the medicine containing Ebastine.

Q: Is Ebastine used for pet allergies or only seasonal/environmental ones?

The medicine is indicated for the symptomatic treatment of allergic rhinitis (seasonal and perennial) and chronic urticaria. This covers symptoms resulting from exposure to common environmental allergens.

Q: Is the full effect of Ebastine reached after the first dose or after several days?

Clinical information suggests that the efficacy for symptom relief can be observed starting from the first day of treatment. The drug is formulated for a sustained effect, and efficacy is maintained with continued once-daily use.

Q: Why is caution advised when taking Ebastine with drugs that affect the heart's QTc interval?

Caution is advised because taking Ebastine with other medicines known to prolong the QTc interval can carry an increased risk of QTc prolongation. This potential additive effect impacts the heart's electrical activity.

Q: What is the recommended approach for managing a missed dose of Ebastine, as described in patient leaflets?

Patient leaflets generally advise taking the missed dose as soon as you remember, unless it is nearly time for your next scheduled dose. If that is the case, you should skip the missed dose and resume your regular schedule. Patient information emphasizes that a double dose should not be taken.

Q: Does Ebastine contain lactose or other common allergens mentioned in official documents?

The official labeling for certain formulations of Ebastine, such as the orodispersible tablets, explicitly lists excipients that include lactose monohydrate and aspartame (E951). Patients with known sensitivities to these ingredients may need to review the specific product information.

Q: What is the difference between seasonal allergic rhinitis and perennial allergic rhinitis, as relates to Ebastine use?

Ebastine is indicated for both seasonal and perennial allergic rhinitis. Seasonal allergic rhinitis typically involves symptoms that occur during specific times of the year (like hay fever season), while perennial allergic rhinitis involves symptoms that persist year-round.

Q: Can Ebastine be taken at the same time every day, or does the timing matter?

The medicine is meant to be taken once daily. While the drug may be taken with or without food, patient information often suggests taking it around the same time each day to maintain a consistent dosing schedule.

Storage and Disposal of Ebastine (AERIUS)

The storage and disposal instructions for Ebastine are strictly based on official regulatory labeling.

Storage Requirements

The product does not require any special temperature storage conditions for some formulations, but it must be kept in its original package for protection from moisture. This is essential for maintaining product stability. For safety, the medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Ebastine must not be disposed of via wastewater or household waste. All disposal of the medicinal product must be handled in accordance with local requirements for pharmaceutical waste.